MORINAGA-MILK-INDUSTRY
8.8.2024 20:01:28 CEST | Business Wire | Press release
Morinaga Milk Industry Co., Ltd. (TOKYO:2264), a leading Japanese dairy product company, today announced its proprietary probiotic Bifidobacterium infantis M-63 was approved by the National Health Commission (NHC) of the People’s Republic of China as a new food ingredient for use in infant and children foods (under the age of three) on 25 July, 2024. This approval marks a significant milestone for the company, making it the only Japanese firm to have three bifidobacteria strains registered for use in China’s infant and toddler food market1.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240808893280/en/
Bifidobacterium infantis M-63 is a unique probiotic strain of human-residential bifidobacteria (HRB) – bifidobacteria that naturally reside in the human gut – and is renowned for its ability to utilize human milk oligosaccharides (HMO) found in breast milk, significantly improving the intestinal environment of healthy full-term infants. (Graphic: Business Wire)
*1 Source: Public announcement published on the website of the China National Center for Food Safety Risk Assessment (August 5, 2024)
The newly registered Bifidobacterium infantis M-63 joins Morinaga Milk’s other approved strains, Bifidobacterium breve M-16V and Bifidobacterium longum BB536. All three strains are now permitted for use in foods for children under three years old in China, meeting the country's stringent nutritional and safety standards.
Expanding Global Presence
This approval aligns with Morinaga Milk’s 10-year vision to become a globally recognized company with a significant international presence. As part of this vision, the company aims to achieve a Global Business sales ratio of 15% or more by the fiscal year ending in March 2029. The approval of Bifidobacterium infantis M-63 represents a strategic step towards this goal, allowing Morinaga Milk to strengthen its bacteria business in the Chinese market, which accounts for more than 40% of the global formula milk market and is the second-largest supplement market worldwide2.
*2 Source: Survey by Euromonitor International (May 2024), based on retail sales prices
Health Benefits of Bifidobacterium infantis M-63
Bifidobacterium infantis M-63 is a unique probiotic strain of human-residential bifidobacteria (HRB) – bifidobacteria that naturally reside in the human gut – and is renowned for its ability to utilize human milk oligosaccharides (HMO) found in breast milk, significantly improving the intestinal environment of healthy full-term infants. With China's recent approval of HMO use in formula milk in October 20233, the combination of Bifidobacterium infantis M-63 and HMO is expected to support the growth of beneficial intestinal bacteria, enhancing the development and health of infants and toddlers4.
*3 Source: National Health Commission of the People’s Republic of China, No. 8, 2023 (Sept. 22, 2023)
*4 Source: Mintel, “HMOs approval in China infant formula is a game changer” (Jan. 2024)
Probiotics strain of bifidobacteria registered as New Food Ingredients in China |
|
Strain |
Registration date |
Bifidobacterium breve M-16V Registered name: 短双歧杆菌 M-16V |
2016 |
Bifidobacterium longum subsp. longum BB536 Registered name: 长双歧杆菌长亚种 BB536 |
2022 |
Bifidobacterium longum subsp. infantis M-63 Registered name: 长双歧杆菌婴儿亚种M-63 |
2024 |
* All three strains are approved for use in foods for infants and toddlers under the age of three. |
|
Commitment to Quality and Research
Morinaga Milk has been at the forefront of bifidobacteria research since discovering Bifidobacterium longum BB536 in 1969. The company leads globally in the number of clinical research papers on bifidobacteria, underlining its commitment to advancing scientific understanding and improving public health.
Future Prospects
The registration of Bifidobacterium infantis M-63 paves the way for its use in a wide range of products. Morinaga Milk plans to leverage this approval to expand collaborations with major formula milk manufacturers and promote supplements and other related products in China and globally. By providing accurate information on the benefits of Bifidobacterium infantis M-63 to consumers and partners, Morinaga Milk aims to enhance the health and nutrition of people worldwide.
About Morinaga Milk Industry
Morinaga Milk Industry Co., Ltd. is one of the leading dairy product companies in Japan, with over a century of history in harnessing the nutritional properties of dairy products and functional ingredients. Morinaga Milk is also a key global probiotics manufacturer that excels in innovative technology and offers a premium line of probiotics and functional ingredients worldwide. Since the 1960s, Morinaga Milk has been engaged in research on the safety, functional health benefits, and mechanisms of action of probiotic bifidobacteria to better understand their role in maintaining human health. For more information about Morinaga Human-Residential Bifidobacteria (HRB) probiotics, please visit us at https://morinagamilk-ingredients.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240808893280/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Siren Fusion 2026: The Convergence of People, Technology and Ideas4.3.2026 14:30:00 CET | Press release
An Invitation-Only Summit for Global Intelligence, National Security and Investigative Leaders Siren today announced Siren Fusion 2026, its inaugural global summit convening senior investigators, national security leaders and AI innovators for a high-trust forum on the future of investigative intelligence. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304240853/en/ Siren Fusion 2026 is the convergence of people, technology and ideas, in Galway, Ireland. An invitation-only summit for global intelligence, national security and investigative leaders. Taking place in Galway, Ireland, Fusion is the deliberate convergence of people, technology and ideas within a national security frame. Structured as an educational and strategic forum rather than a conventional conference, Fusion 2026 focuses on the issues that now define the intelligence and law enforcement agenda: Geopolitical instability AI-driven investigative transformati
Mary Kay Goes for Gold in Global Manufacturing Standards4.3.2026 14:11:00 CET | Press release
Quality, Certified: Mary Kay Achieves ISO 22716 Mary Kay Inc., a global direct sales leader in beauty and skincare innovation, has achieved ISO 22716 certification, the internationally recognized gold standard for cosmetic Good Manufacturing Practices (GMP), reinforcing the company’s unwavering commitment to product quality, safety, and consumer trust worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304100367/en/ Chaun Harper, Chief Supply Chain Officer at Mary Kay Inc., emphasized the broader significance of the milestone: “At Mary Kay, quality is not a checkbox – it is a promise, an operational framework, and a culture. (Photo Credit: Mary Kay Inc.) Key Data Points About Mary Kay’s Global Manufacturing: Built on 26 acres of land, Mary Kay’s state-of-the-art, Silver LEED-certified Richard R. Rogers Manufacturing and R&D Center (R3) is located in Lewisville, Texas. R3 is a $100+ million investment and is a 453,00
NelsonHall Recognizes LTM as a Leader in GenAI & Process Automation for Banking4.3.2026 13:45:00 CET | Press release
LTM, the Business Creativity partner to the world’s largest enterprises, has been recognized as a Leader in the ‘Overall’ market segment in the NelsonHall NEAT Evaluation for GenAI & Process Automation in Banking 2025. In the NEAT framework, Leaders are vendors that demonstrate high capability relative to peers in delivering immediate client benefit while also meeting future client requirements. The recognition positions LTM among the top-performing vendors evaluated for their ability to deliver both immediate business impact and long-term innovation capability in GenAI and process automation services for the banking sector. The evaluation highlights LTM’s depth of experience in financial services, which accounts for a large portion of its overall revenues, and its focused investments in GenAI, agentic AI, and process automation capabilities delivered through its BlueVerse™ platform. LTM has digital agents dedicated to manage GenAI and process automation services, supporting banking cl
Americhem Expands Aircraft Interior Portfolio with PFAS-Free Thermoplastic Platform Meeting 55/55 OSU, Low Smoke, and Low Toxicity Requirements4.3.2026 13:00:00 CET | Press release
Americhem is expanding its aircraft interior materials portfolio with ColorFast® SFT5500, a PFAS-free high-performance thermoplastic engineered to meet FAA 14 CFR 25.853, Appendix F, Part IV, 55/55 OSU heat release requirements while delivering low smoke and low toxicity characteristics for aircraft interior applications. PFAS-free thermoplastic systems capable of achieving 55/55 OSU performance while maintaining low smoke and low toxicity characteristics remain limited in the aerospace market. ColorFast® SFT5500 addresses this need with demonstrated 55/55 OSU heat release performance, low smoke emission characteristics, and low flaming-mode toxicity performance in a high-performance thermoplastic platform designed specifically for injection-molded interior components. Aircraft interior thermoplastics must meet stringent fire standards while maintaining durability, thermal stability, and process consistency. As legacy fluorinated material systems face increasing regulatory scrutiny, ma
NETSCOUT Reveals Qualitative Shifts in DDoS Attack Sophistication, Infrastructure Capacity, and Threat Actor Capabilities4.3.2026 12:05:00 CET | Press release
AI Adoption, coordinated botnets, and persistent hacktivists groups drove millions of attacks NETSCOUT® SYSTEMS, INC. (NASDAQ: NTCT), today released its second half of the year 2025 Distributed Denial-of-Service (DDoS) Threat Intelligence Report, revealing sophisticated attacker collaboration, resilient botnets, and compromised IoT infrastructure that drove more than eight million DDoS attacks worldwide – some as large as 30 terabits per second (Tbps) – marking a new era of hyper-scale, coordinated threat activity that continues to outpace global takedown efforts. Meanwhile, the accelerating growth of DDoS-for-hire services is empowering a broader range of threat actors, intensifying operational risk to digitally connected organizations and enterprises. Implications for security professionals extend far beyond volumetric concerns and include reconnaissance and adaptive evasion which challenge traditional defense paradigms. Organizations must match adversarial innovation with intelligen
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom